487 related articles for article (PubMed ID: 23417759)
1. Efficacy and safety of deferasirox in myelodysplastic syndromes.
Breccia M; Alimena G
Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
[TBL] [Abstract][Full Text] [Related]
2. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
3. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
4. Iron chelation therapy in MDS: what have we learnt recently?
Schmid M
Blood Rev; 2009 Dec; 23 Suppl 1():S21-5. PubMed ID: 20116636
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
[TBL] [Abstract][Full Text] [Related]
6. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Goldberg SL
Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
[TBL] [Abstract][Full Text] [Related]
7. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
Gattermann N; Finelli C; Porta MD; Fenaux P; Ganser A; Guerci-Bresler A; Schmid M; Taylor K; Vassilieff D; Habr D; Domokos G; Roubert B; Rose C;
Leuk Res; 2010 Sep; 34(9):1143-50. PubMed ID: 20451251
[TBL] [Abstract][Full Text] [Related]
8. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
Ghoti H; Fibach E; Westerman M; Gordana O; Ganz T; Rachmilewitz EA
Br J Haematol; 2011 Apr; 153(1):118-20. PubMed ID: 21332711
[TBL] [Abstract][Full Text] [Related]
9. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
Metzgeroth G; Dinter D; Schultheis B; Dorn-Beineke A; Lutz K; Leismann O; Hehlmann R; Hastka J
Ann Hematol; 2009 Apr; 88(4):301-10. PubMed ID: 18758781
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
[TBL] [Abstract][Full Text] [Related]
11. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
[TBL] [Abstract][Full Text] [Related]
12. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of deferasirox.
Cappellini MD
Blood Rev; 2008 Dec; 22 Suppl 2():S35-41. PubMed ID: 19059055
[TBL] [Abstract][Full Text] [Related]
14. Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Breccia M; Finsinger P; Loglisci G; Federico V; Santopietro M; Colafigli G; Petrucci L; Salaroli A; Serrao A; Latagliata R; Alimena G
Ann Hematol; 2012 Sep; 91(9):1345-9. PubMed ID: 22569854
[TBL] [Abstract][Full Text] [Related]
15. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.
Greenberg PL; Koller CA; Cabantchik ZI; Warsi G; Glynos T; Paley C; Schiffer C
Leuk Res; 2010 Dec; 34(12):1560-5. PubMed ID: 20615548
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox--an oral agent for chronic iron overload.
Vanorden HE; Hagemann TM
Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
[TBL] [Abstract][Full Text] [Related]
17. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
18. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
Gattermann N; Jarisch A; Schlag R; Blumenstengel K; Goebeler M; Groschek M; Losem C; Procaccianti M; Junkes A; Leismann O; Germing U
Eur J Haematol; 2012 Mar; 88(3):260-8. PubMed ID: 22023452
[TBL] [Abstract][Full Text] [Related]
19. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
Jabbour E; Garcia-Manero G; Taher A; Kantarjian HM
Oncologist; 2009 May; 14(5):489-96. PubMed ID: 19365094
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
Porter JB; Elalfy MS; Taher AT; Aydinok Y; Chan LL; Lee SH; Sutcharitchan P; Habr D; Martin N; El-Beshlawy A
Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
